NCT05455294 is a Phase 1 clinical trial of Navitoclax in Myeloid Malignancy, sponsored by Jacqueline Garcia, MD.

Who is sponsoring NCT05455294?

NCT05455294 is sponsored by Jacqueline Garcia, MD.

What drugs are being tested in NCT05455294?

Interventions in NCT05455294: Navitoclax, Venetoclax, Decitabine.

What condition does NCT05455294 study?

NCT05455294 studies Myeloid Malignancy, Myelodysplastic Syndromes, Myelofibrosis, Acute Myeloid Leukemia, Myeloproliferative Neoplasm.

Is NCT05455294 still recruiting?

NCT05455294 is currently active, enrolled. Last updated 28 January 2026.

Last reviewed 2026-01-28 · How we verify

NCT05455294

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

Active, enrolled Phase 1 Last updated 28 January 2026

What this trial tests

Phase 1 trial testing Navitoclax in Myeloid Malignancy in 16 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

18 July 2022

Primary endpoint
17 April 2024

31 December 2026

Quick facts

Lead sponsor	Jacqueline Garcia, MD
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	18 July 2022
Primary completion	17 April 2024
Estimated completion	31 December 2026
Sites	3 locations across United States

Drugs / interventions tested

Navitoclax — full drug profile →
Venetoclax (venetoclax) — full drug profile →
Decitabine (decitabine) — full drug profile →

Conditions studied

Myeloid Malignancy — all drugs for Myeloid Malignancy →
Myelodysplastic Syndromes — all drugs for Myelodysplastic Syndromes →
Myelofibrosis — all drugs for Myelofibrosis →
Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →

Sponsor

Jacqueline Garcia, MD — full company profile →

Who can join

18 and older, any sex, with Myeloid Malignancy or Myelodysplastic Syndromes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research study is to test the safety of a new three drug combination of navitoclax, decitabine, and venetoclax to treat advanced myeloid malignancies. The names of the drugs involved in this study are: * Venetoclax * Decitabine * Navitoclax

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting senescence as an anticancer therapy.
Bousset L, Gil J. · · 2022 · cited 70× · PMID 36065138 · DOI 10.1002/1878-0261.13312
Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance.
Song J, Yang P, Chen C, Ding W, et al · · 2025 · cited 40× · PMID 40675967 · DOI 10.1038/s41392-025-02266-z
Programmed cell death: molecular mechanisms, biological functions, diseases, and therapeutic targets.
Qian S, Long Y, Tan G, Li X, et al · · 2024 · cited 24× · PMID 39619229 · DOI 10.1002/mco2.70024
The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable Target.
Verzella D, Cornice J, Arboretto P, Vecchiotti D, et al · · 2022 · cited 23× · PMID 36140335 · DOI 10.3390/biomedicines10092233
Emerging drugs targeting cellular redox homeostasis to eliminate acute myeloid leukemia stem cells.
Costa RGA, Silva SLR, Dias IRSB, Oliveira MS, et al · · 2023 · cited 16× · PMID 37031536 · DOI 10.1016/j.redox.2023.102692
The Interplay between Autophagy and Mitochondria in Cancer.
Zdanowicz A, Grosicka-Maciąg E. · · 2024 · cited 9× · PMID 39273093 · DOI 10.3390/ijms25179143
Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment.
Chomczyk M, Gazzola L, Dash S, Firmanty P, et al · · 2024 · cited 6× · PMID 39161899 · DOI 10.3389/fphar.2024.1409210
Novel therapies upon failure of HMA plus venetoclax.
Chan O, Walker AR. · · 2023 · cited 3× · PMID 38066883 · DOI 10.1182/hematology.2023000456

Verify or expand the search:

Other trials of Navitoclax

Trials testing the same drug.

NCT06210750 — Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) · Phase 2 · withdrawn
NCT05740449 — HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Mal · Phase 1, PHASE2 · withdrawn
NCT05864742 — Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma · Phase 2 · active not recruiting
NCT05564650 — Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome · Phase 1 · active not recruiting
NCT05358639 — Combination of Olaparib and Navitoclax in Women with HGSC and TNBC · Phase 1 · active not recruiting

Other recruiting trials for Myeloid Malignancy

Currently open trials in the same condition.

NCT07263074 — Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories · NA · recruiting
NCT06594445 — HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML · Phase 1 · recruiting
NCT06621212 — Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML · Phase 2 · recruiting
NCT06378437 — A Study of GLB-001 in Patients With Myeloid Malignancies · Phase 1 · recruiting
NCT05875805 — A Telehealth Advance Care Planning Intervention · NA · recruiting

Other Jacqueline Garcia, MD trials

Trials by the same sponsor.

NCT07148180 — A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: · Phase 1, PHASE2 · recruiting
NCT03613532 — Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN · Phase 1 · active not recruiting
NCT03125239 — Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05455294 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jacqueline Garcia, MD
Last refreshed: 28 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05455294.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing